Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)  - Pipeline Review, H2 2016', provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)  targeted pipeline therapeutics. 

The report provides comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)  targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) 
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)  targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)  targeted therapeutics and enlists all their major and minor projects 
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)  targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)  targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)  development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) Overview 8
Therapeutics Development 9
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Products under Development by Stage of Development 9
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Products under Development by Therapy Area 10
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Products under Development by Indication 11
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Products under Development by Companies 15
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Products under Development by Universities/Institutes 18
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics Assessment 20
Assessment by Monotherapy/Combination Products 20
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Companies Involved in Therapeutics Development 27
AbbVie Inc 27
Apexigen, Inc. 28
Apogenix GmbH 29
Boehringer Ingelheim GmbH 30
Bristol-Myers Squibb Company 31
Celldex Therapeutics, Inc. 32
F. Hoffmann-La Roche Ltd. 33
ImmuNext, Inc. 34
Johnson & Johnson 35
Kyowa Hakko Kirin Co., Ltd. 36
Novartis AG 37
Seattle Genetics, Inc. 38
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Drug Profiles 39
2C-10 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
ABBV-428 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
APG-1233 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
APX-005M - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
BI-655064 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
bleselumab - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
BMS-986090 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
CFZ-533 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
FFP-104 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
JNJ-64457107 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
KGYY-15 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Monoclonal Antibodies to Agonize CD40 and FCGR2B for B-cell Lymphoma and Melanoma - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Monoclonal Antibodies to Agonize CD40 for Lymphoma - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Monoclonal Antibody to Agonize CD40 for Oncology - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
RG-7876 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
SEA-CD40 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Dormant Projects 60
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Discontinued Products 62
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Featured News & Press Releases 63
Apr 18, 2016: Seattle Genetics Highlights Data on SEA-CD40 at the American Association for Cancer Research Annual Meeting 63
Apr 13, 2016: Apexigen to Present Data on Its Novel Immuno-Oncology Program APX005M at Upcoming Cancer Conferences 63
Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohn's Disease with anti-CD40 Monoclonal Antibody 64
Nov 17, 2015: Apexigen Presents Positive Data for APX005M in Podium Presentation at Immune Checkpoint Inhibitors (ICI) Europe 64
Nov 06, 2015: Apexigen Presents Preclinical Data from Novel Immuno-Oncology Candidate APX005M at SITC 2015 Meeting 65
Jun 16, 2015: Apexigen Doses First Patient in Phase 1 Clinical Trial of Its Immuno-oncology Therapeutic Antibody APX005M 66
May 28, 2015: Alligator Bioscience Phase 1 Trial Benefits from Cobra Biologics maxXpress Platform 66
Apr 27, 2015: First Patient Dosed by Alligator Bioscience in a Clinical Phase 1 Multicenter Trial 67
Apr 07, 2015: Alligator Bioscience Starts a Clinical Phase 1 Multicenter Trial 67
Feb 17, 2015: Seattle Genetics Advances Immuno-Oncology Program SEA-CD40 Into Phase 1 Clinical Trial for Advanced Solid Tumors 68
Dec 05, 2012: Boehringer Ingelheim And Apexigen Sign Manufacturing Agreement For Process Development And Early Stage Clinical Supply 68
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70

List of Tables

Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Indication, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
Assessment by Monotherapy/Combination Products, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 26
Pipeline by AbbVie Inc, H2 2016 27
Pipeline by Apexigen, Inc., H2 2016 28
Pipeline by Apogenix GmbH, H2 2016 29
Pipeline by Boehringer Ingelheim GmbH, H2 2016 30
Pipeline by Bristol-Myers Squibb Company, H2 2016 31
Pipeline by Celldex Therapeutics, Inc., H2 2016 32
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 33
Pipeline by ImmuNext, Inc., H2 2016 34
Pipeline by Johnson & Johnson, H2 2016 35
Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 36
Pipeline by Novartis AG, H2 2016 37
Pipeline by Seattle Genetics, Inc., H2 2016 38
Dormant Projects, H2 2016 60
Dormant Projects (Contd..1), H2 2016 61
Discontinued Products, H2 2016 62